Skeletal Dysplasia Account Manager - Denver, CO/Salt Lake City, UT
BridgeBio
August 21, 2026
Remote friendly (United States)
United States
Sales
What You Will Do
The Skeletal Dysplasia Account Manager will drive the launch of Infigratinib (first-in-class therapy for achondroplasia), bringing deep clinical acumen and partnering with providers and families.
Location
West Region (multiple territories): San Diego, Los Angeles, San Jose, Seattle, Omaha, Denver, San Francisco.
Responsibilities
- Develop and execute a territory business plan targeting geneticists, pediatric endocrinologists, orthopedic specialists, pediatricians, and multi-disciplinary skeletal dysplasia clinic teams to meet/exceed sales goals.
- Demonstrate deep expertise in Infigratinib, achondroplasia, and the broader skeletal dysplasia landscape; engage HCPs in clinically relevant, compliant discussions.
- Use sales/target data to identify growth opportunities and proactively address territory challenges.
- Anticipate business challenges, adjust priorities, and develop solutions.
- Partner compliantly with Field Medical Directors, Field Reimbursement Managers, Family Account Managers, and the HUB to maximize customer/family satisfaction.
- Build and maintain KOL relationships with Marketing and Medical Affairs to expand advocacy.
- Operate with an “One Bridge” mindset and represent the company with integrity.
- Maintain proficiency in selling skills, clinical/market/product knowledge, and territory business environment.
- Ensure all activities comply with applicable regulations and Pharma guidelines.
Qualifications
- 8–10 years pharmaceutical/biotech; 4+ years in rare disease/genetic disease/skeletal dysplasia (achondroplasia or pediatric rare disease preferred).
- BS/BA required; MBA a plus.
- Extensive travel required.
- Product/indication launch experience.
- Account management experience.
- Strong leadership, communication, and organizational skills.
- AI fluency.
- Integrity and commitment to ethical/compliance culture.
Compensation (California)
- Salary: $155,000–$210,000 USD.
The Skeletal Dysplasia Account Manager will drive the launch of Infigratinib (first-in-class therapy for achondroplasia), bringing deep clinical acumen and partnering with providers and families.
Location
West Region (multiple territories): San Diego, Los Angeles, San Jose, Seattle, Omaha, Denver, San Francisco.
Responsibilities
- Develop and execute a territory business plan targeting geneticists, pediatric endocrinologists, orthopedic specialists, pediatricians, and multi-disciplinary skeletal dysplasia clinic teams to meet/exceed sales goals.
- Demonstrate deep expertise in Infigratinib, achondroplasia, and the broader skeletal dysplasia landscape; engage HCPs in clinically relevant, compliant discussions.
- Use sales/target data to identify growth opportunities and proactively address territory challenges.
- Anticipate business challenges, adjust priorities, and develop solutions.
- Partner compliantly with Field Medical Directors, Field Reimbursement Managers, Family Account Managers, and the HUB to maximize customer/family satisfaction.
- Build and maintain KOL relationships with Marketing and Medical Affairs to expand advocacy.
- Operate with an “One Bridge” mindset and represent the company with integrity.
- Maintain proficiency in selling skills, clinical/market/product knowledge, and territory business environment.
- Ensure all activities comply with applicable regulations and Pharma guidelines.
Qualifications
- 8–10 years pharmaceutical/biotech; 4+ years in rare disease/genetic disease/skeletal dysplasia (achondroplasia or pediatric rare disease preferred).
- BS/BA required; MBA a plus.
- Extensive travel required.
- Product/indication launch experience.
- Account management experience.
- Strong leadership, communication, and organizational skills.
- AI fluency.
- Integrity and commitment to ethical/compliance culture.
Compensation (California)
- Salary: $155,000–$210,000 USD.